Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types
- PDF / 1,749,766 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 15 Downloads / 167 Views
PRECLINICAL STUDIES
Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types Man-Fei Zhao 1 & Gong-Da Liang 1 & Yu-Jie Zhou 2,3 & Zhi-Ping Chi 2,3 & He Zhuang 2,3 & Song-Ling Zhu 2,3 & Yao Wang 2,3 & Gui-Rong Liu 2,3 & Jing-Bo Zhao 1 & Shu-Lin Liu 2,3,4 Received: 4 October 2019 / Accepted: 28 January 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Summary Cancer is one of the leading causes of death worldwide, but effective therapies remain the topic of many research activities. Many recent studies have thus focused on particular gut microbiota due to their important roles in treating cancers, but very few microbes of therapeutic value have been reported. In this study, we isolated four bacterial strains, BY38, BY40, BY43 and BY45, from the fecal specimens of healthy individuals and cancer patients. The treatment of cancer cells with the products of these cultured bacteria induced significant inhibitory effects on the proliferation of ovarian cancer cells and colorectal cancer cells in a dose-dependent manner. A phylogenetic analysis showed that the four anticancer strains belong to the genus Bacillus, and flow cytometry assays indicated that the inhibitory effects might be achieved through the induction of cell apoptosis. These results suggest that these bacteria could be novel and promising anticancer agents against cancers. Keywords Gut microbiota . Bacterial products . Cancer . Apoptosis . Bacillus
Introduction Cancer causes enormous disease and economic burdens on society [1, 2], and its incidence is rapidly increasing worldwide, due mostly to the prevalence of risk factors, such as
unhealthy lifestyles and harmful environments, in addition to the inheritance of susceptibility genes [3–6]. Even more urgent in the human struggle against cancer, however, is the lack of effective therapies. Traditional cancer therapies and even modern immune checkpoint therapies have various
* Gui-Rong Liu [email protected]
Song-Ling Zhu [email protected]
* Jing-Bo Zhao [email protected]
Yao Wang [email protected]
* Shu-Lin Liu [email protected] 1
Department of Epidemiology, Public Health School, Harbin Medical University, Harbin, Heilongjiang Province, China
2
Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, Heilongjiang Province, China
3
HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, Heilongjiang Province, China
4
Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada
Man-Fei Zhao [email protected] Gong-Da Liang [email protected] Yu-Jie Zhou [email protected] Zhi-Ping Chi [email protected] He Zhuang [email protected]
Invest New Drugs
limitations [7–11]. Increasing lines of evidence have indicated the key roles of the gut microbiota in fighting cancers [12–14], and interestingly, several recent studies have revealed tha
Data Loading...
